Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13596303 | 0.98 | GLS (0.37) | GLSGBA1NPC1CA12CA1 | |
| SCHEMBL13596304 | 0.96 | GLS (0.37) | GLSGBA1NPC1CA12CA1 | |
| SCHEMBL13596301 | 0.96 | GLS (0.37) | GLSGBA1NPC1CA12CA1 | |
| SCHEMBL19592563 | 0.90 | GLS (0.37) | GLSGBA1NPC1CA12CA1 | |
| SCHEMBL18792801 | 0.89 | GLS (0.37) | GLSGBA1CA12CA1CA2 | |
| SCHEMBL19632219 | 0.89 | GLS (0.37) | GLSGBA1CA12CA1CA2 | |
| SCHEMBL12453912 | 0.89 | GBA1 (0.42) | GLSGBA1 | |
| SCHEMBL19592512 | 0.89 | GLS (0.38) | GLSGBA1CA12CA1CA2 | |
| SCHEMBL19389613 | 0.89 | GBA1 (0.41) | GLSGBA1NPC1CA12CA1 | |
| SCHEMBL19592515 | 0.88 | GLS (0.36) | GLSGBA1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | SYNTARGA BV (NL) | 2021-07-06 | — | — | US | disclosed |
| US-20180147289-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2018-05-31 | — | — | US | disclosed |
| US-20180133316-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2018-05-17 | — | — | US | disclosed |
| US-9901567-B2 | Substituted CC-1065 analogs and their conjugates | SYNTARGA B.V. (NL) | 2018-02-27 | — | — | US | disclosed |
| US-20170333567-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2017-11-23 | — | — | US | disclosed |
| US-9815784-B2 | CC-1065 analogs and their conjugates | SYNTARGA B.V. (NL) | 2017-11-14 | — | — | US | disclosed |
| US-20170274090-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2017-09-28 | — | — | US | disclosed |
| US-9629924-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | SYNTARGA BV (NL) | 2017-04-25 | — | — | US | disclosed |
| US-8940784-B2 | Water-soluble CC-1065 analogs and their conjugates | SYNTARGA B.V. (NL) | 2015-01-27 | — | — | US | disclosed |
| US-20090318668-A1 | Water-Soluble CC-1065 Analogs and Their Conjugates | Georg-August-Universität Göttingen Stiftung öffentlichen Rechts (ohne Bereich Humanmedizin) (DE) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170274090-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | GLS 991/4885GBA1 417/4885NPC1 4105/4885 |
| US-20090318668-A1 | Water-Soluble CC-1065 Analogs and Their Conjugates | PCNA, DCK, BAD | GLS 737/4885GBA1 486/4885NPC1 3451/4885 |
| US-20170333567-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | GLS 991/4885GBA1 417/4885NPC1 4105/4885 |
| US-20180133316-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | GLS 991/4885GBA1 417/4885NPC1 4105/4885 |
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | PCNA, DCLRE1A, CDC5L | GLS 937/4885GBA1 423/4885NPC1 4122/4885 |
| US-20180147289-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | GLS 991/4885GBA1 417/4885NPC1 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.